-- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 – -- Initial readout expected as ear...
Tome Biosciences, Inc., the programmable genomic integration (PGI) company, announces that it has acquired Replace Therapeutics Inc., a private biote...
Cell BioEngines, Inc., a clinical-stage biotechnology company focused on delivering novel, innovative stem cell and immune cell therapies to address blood ...
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neur...
The European Patent office granted patent No. 3105587 titled 'Method of Qualifying of Cells' for a method of qualifying whether a cell population is a suit...
Initial clinical efficacy data expected by year-end 2024 and durability data expected in 2025 – – SENTI-202 is a potential first-in-class of...
Company to discontinue its three Phase 3 posoleucel studies following separate, pre-planned DSMB futility analyses concluding the studies were unlikely to ...
Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, and Akron Bio (“Akron&...
TriMas (NASDAQ: TRS) announced that its Intertech business, part of the TriMas Life Sciences division, has expanded its cleanroom capacity at its Den...
Friedreich’s ataxia is a genetic, debilitating and life-shortening neuromuscular disease1 Milestone highlights Biogen’s growing portfolio in...
"We're excited to work with Rutgers Cancer Institute in their efforts to optimize therapeutic strategies for patients with early-stage breast cancer," said...
OmniAb, Inc. announces the presentation of new scientific data on its OmnidAb™ platform, the industry’s first and only transgenic chicken...
Roivant (Nasdaq: ROIV) announced the completion of the previously announced acquisition by Roche (SIX: RO, ROG; OTCQX: RHHBY) of Telavant, for an upf...
AstraZeneca has entered into a definitive agreement to acquire Icosavax, Inc. (NASDAQ: ICVX), a US-based clinical-stage biopharmaceutical company focused o...
© 2025 Biopharma Boardroom. All Rights Reserved.
